



To: Chief Financial Officers – All Hospitals

From: Dennis N. Phelps – Deputy Director-Audit & Compliance

Re: Charging for Monoclonal Antibody Drugs

Date: November 29, 2022

Adam Kane, Esq
Chairman

Joseph Antos, PhD
Vice-Chairman

Victoria W. Bayless

Stacia Cohen, RN, MBA

James N. Elliott, MD

Maulik Joshi, DrPH

Sam Malhotra

.....
Katie Wunderlich
Executive Director

William Henderson
Director
Medical Economics & Data Analytics

Allan Pack
Director
Population-Based Methodologies

Gerard J. Schmith
Director
Revenue & Regulation Compliance

Consistent with its policy for COVID-19 testing, the HSCRC has determined that Monoclonal Antibody drugs previously, but no longer provided free to hospitals, shall be charged to patients at the Medicare price for the duration of the federal Public Health Emergency. Although it may be extended, the federal Public Health Emergency is currently scheduled to expire January 11, 2023.

Monoclonal Antibody drugs include but are not limited to:

Bebtelovimab 175mg Medicare Price \$2,394

Once the federal Public Health Emergency has expired, hospitals will develop charges for these drugs utilizing the standard HSCRC drug pricing methodology.

If you have any questions, you may contact me at dennis.phelps@maryland.gov.